Abbott India share price & results
- Jun 2026
- Sept 2026
Abbott Laboratories' Indian arm, marketing branded pharma, vaccines & nutritionals across 6 therapy areas
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,814 | +4.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 29.0 | +3.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 429 | +17.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 35.86 | −1.3 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 18.86 | +3.9 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 6.30 | −1.5 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −14.8% 1Y
1Y: ₹29,930 on 24 Oct 2025 → ₹25,515. High ₹30,205 (25 Nov 2025), low ₹25,030 (23 Oct 2026).
- Previous close
- ₹25,225
- Market cap
- ₹54.2k Cr
- 52-week range
- ₹25,030 – ₹30,205
- One year
- −14.29%
- Price to earnings (TTM to Jun 2026)
- 33.58×
- Return on equity (TTM to Jun 2026)
- 35.86%
Overview
- Symbol
- NSE:ABBOTINDIA
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Abbott India Limited does
Based on the company's own presentations, annual report and earnings calls.
Abbott India Limited is the Indian pharmaceutical subsidiary of global healthcare group Abbott Laboratories, engaged in the development, manufacture and marketing of branded generic medicines, vaccines and nutritional/wellness products. It earns through sale of these branded products via trade channels and institutions, promoted to doctors and healthcare professionals by its own field sales force. The company covers six therapy areas — Gastroenterology, Women's Health, Metabolics, Central Nervous System (CNS), Vaccines and Multi-Specialty — and manufactures a portion of its products at its own facility in Goa, sourcing the rest from third-party manufacturers and group affiliates.
Segments
- Gastroenterology
- Women's Health
- Metabolics
- Central Nervous System (CNS)
- Vaccines
- Multi-Specialty
- Products in portfolio
- 130+
- Brands ranked #1 or #2 in their respective participated markets
- 16
- Brands in Top 100 of Indian Pharmaceutical Market (IPM)
- 8
- Brands in Top 300 of IPM
- 10
- New products launched in FY 2024-25
- 7
- Own manufacturing facility
- Goa plant
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +17% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 | 1,814 |
| Expenses | 1,194 | 1,178 | 1,176 | 1,293 | 1,255 | 1,261 | 1,229 | 1,291 |
| Operating profit | 439 | 436 | 429 | 446 | 502 | 463 | 481 | 522 |
| Operating margin | 27.0% | 27.0% | 27.0% | 26.0% | 29.0% | 27.0% | 28.0% | 29.0% |
| Other income | 60 | 72 | 76 | 73 | 70 | 70 | 76 | 75 |
| Interest | 2 | 2 | 4 | 6 | 8 | 5 | 6 | 6 |
| Depreciation | 18 | 18 | 18 | 19 | 19 | 19 | 19 | 20 |
| Profit before tax | 479 | 488 | 483 | 493 | 546 | 509 | 531 | 572 |
| Tax rate | 25.0% | 26.0% | 24.0% | 26.0% | 24.0% | 26.0% | 26.0% | 25.0% |
| Net profit | 359 | 361 | 367 | 366 | 415 | 376 | 395 | 429 |
| EPS (₹ per share) | 168.76 | 169.78 | 172.73 | 172.18 | 195.43 | 176.93 | 185.86 | 201.66 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 5,348 | 5,849 | 6,410 | 6,929 |
| Expenses | 4,143 | 4,395 | 4,715 | 5,038 |
| Operating profit | 1,205 | 1,454 | 1,695 | 1,892 |
| Other income | 155 | 249 | 275 | 289 |
| Interest | 16 | 12 | 11 | 25 |
| Depreciation | 69 | 71 | 72 | 76 |
| Profit before tax | 1,273 | 1,617 | 1,887 | 2,079 |
| Net profit | 950 | 1,201 | 1,415 | 1,552 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 2,799 | 3,167 | 3,678 | 4,212 | 3,990 | 4,753 |
| Borrowings | 152 | 113 | 83 | 197 | 182 | 172 |
| Other liabilities | 1,253 | 1,254 | 1,411 | 1,487 | 1,501 | 1,556 |
| Total liabilities | 4,224 | 4,556 | 5,193 | 5,917 | 5,694 | 6,502 |
| Fixed assets | 271 | 237 | 225 | 336 | 314 | 331 |
| Capital work in progress | 1 | 4 | 10 | 18 | 23 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 3,952 | 4,315 | 4,958 | 5,563 | 5,357 | 6,165 |
| Total assets | 4,224 | 4,556 | 5,193 | 5,917 | 5,694 | 6,502 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 727 | 948 | 893 | 1,213 | 1,012 | 1,319 |
| Cash from investing | -72 | -396 | -148 | -416 | 182 | -371 |
| Cash from financing | -582 | -637 | -639 | -745 | -925 | -1,066 |
| Net cash flow | 73 | -86 | 107 | 52 | 269 | -118 |
| Free cash flow | 704 | 904 | 860 | 1,165 | 960 | 1,307 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 21 | 21 | 22 | 20 | 22 | 19 |
| Inventory days | 110 | 94 | 80 | 70 | 92 | 94 |
| Days payable | 116 | 122 | 109 | 114 | 110 | 109 |
| Cash conversion cycle | 14 | -6 | -8 | -24 | 3 | 3 |
| Working capital days | 4 | -7 | -8 | -14 | 99 | 2 |
| Return on capital employed | 35.0% | 38.0% | 41.0% | 46.0% | 46.0% | 45.0% |
| Dividend payout | 85.0% | 73.0% | 73.0% | 73.0% | 71.0% | 90.0% |
What the price assumes
ExpensiveTo justify its price of ₹25515, this stock must grow earnings at 24% every year for 7 years. Our analysis caps realistic growth at ~18%. At that growth it is worth ₹18981 — downside of 26%.
- Growth the price implies
- 23.6% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 17.8% a year
- net profit, FY23–FY26 · EPS 17.8%
- The gap
- 0.1 pp
- -26% downside if it only repeats history
Ownership
Who owns it
Promoters hold 74.99% as of Sept 2026; institutions added 0.24 pts since Jun 2026.
- Promoters 74.99%
- Foreign institutions 0.40%
- Domestic institutions 8.99%
- Public 15.62%
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Mutual fund newly disclosed 1.50% held
- Mutual fund +0.25 pp 1.32% held
The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Abbott India Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 50.44% | unchanged | |
| 17.62% | unchanged | |
| 6.92% | unchanged | |
| Mutual fund | 1.50% | newly disclosed |
| Mutual fund | 1.32% | +0.25 pp |
| Mutual fund | 1.01% | −0.06 pp |
| Mutual fund | — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in ABBOTINDIA
Filings to Sep 2026
0 new, 4 added, 6 trimmed, 0 sold out — net −0.06 L shares (−1.0%).
- Held by funds
- ₹1.6k Cr
- 14 schemes
- Biggest holder
- SBI Large and Midcap Fund
- ₹835 Cr · 2.1% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| SBI Large and Midcap Fund SBI Mutual Fund | ₹835 Cr | held | Sep '22 |
| Nippon India Multi Cap Fund Nippon India Mutual Fund | ₹400 Cr | +0.01 L | Oct '21 |
| Nippon India Pharma Fund Nippon India Mutual Fund | ₹213 Cr | +0.00 L | Sep '12 |
| Nippon India Vision Large & Mid Cap Fund Nippon India Mutual Fund | ₹72 Cr | held | Jul '26 |
| Nippon India Retirement Fund - Wealth Creation Scheme Nippon India Mutual Fund | ₹26 Cr | held | Jun '24 |
| Nippon India Nifty Pharma ETF Nippon India Mutual Fund | ₹25 Cr | +0.00 L | Sep '21 |
| SBI Healthcare Opportunities Fund SBI Mutual Fund | ₹14 Cr | −0.03 L | Aug '21 |
| SBI MNC Fund SBI Mutual Fund | ₹14 Cr | −0.05 L | Aug '21 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Sep 2026
4 added, 6 trimmed — net −6,165 shares (−1.0%)
- Funds are sitting on
- +7%
- vs est. average cost
- Held by funds
- ₹1.6k Cr
- 14 schemes · ≈ 2.8% of the company
- Biggest holder
- SBI Large and Midcap Fund
- ₹835 Cr · 2.1% of that fund
- Longest holder
- Nippon India Pharma Fund
- 14y 1m · since Sep '12
Shares held by these funds +25%
Oct '23 6.00 L shares Sep '26
Your own record
Start an Inve Case for Abbott India Limited
Free account: one company. Everything above stays public.
Write why you follow Abbott India Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Abbott India Limited
Guides on how to read this kind of business and the numbers that matter.